Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lindsey Robert Baden, M.D.

Co-Author

This page shows the publications co-authored by Lindsey Baden and Stephen Walsh.
Connection Strength

2.899
  1. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013 Jun 15; 207(12):1888-97.
    View in: PubMed
    Score: 0.531
  2. Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. Vaccine. 2012 Dec 17; 31(1):114-9.
    View in: PubMed
    Score: 0.519
  3. Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. Open Forum Infect Dis. 2021 Jan; 8(1):ofaa606.
    View in: PubMed
    Score: 0.228
  4. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020 10; 7(10):e688-e698.
    View in: PubMed
    Score: 0.224
  5. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.192
  6. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 01; 164(5):313-22.
    View in: PubMed
    Score: 0.162
  7. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. J Infect Dis. 2016 Feb 15; 213(4):541-50.
    View in: PubMed
    Score: 0.159
  8. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. 2015 Feb 15; 211(4):518-28.
    View in: PubMed
    Score: 0.147
  9. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis. 2014 Oct 01; 210(7):1052-61.
    View in: PubMed
    Score: 0.143
  10. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):248-56.
    View in: PubMed
    Score: 0.130
  11. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):240-7.
    View in: PubMed
    Score: 0.130
  12. Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. J Clin Invest. 2021 12 01; 131(23).
    View in: PubMed
    Score: 0.061
  13. Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant. Open Forum Infect Dis. 2021 Dec; 8(12):ofab504.
    View in: PubMed
    Score: 0.061
  14. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349.
    View in: PubMed
    Score: 0.058
  15. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS One. 2019; 14(8):e0219142.
    View in: PubMed
    Score: 0.052
  16. Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Adv. 2018 06 12; 2(11):1272-1276.
    View in: PubMed
    Score: 0.048
  17. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis. 2010 May 01; 201(9):1353-60.
    View in: PubMed
    Score: 0.027
  18. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis. 2010 May 01; 201(9):1361-70.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.